Singapore Reliance on Malaysian MDA Registrations under GN-15 R13

1. Key takeaways

Yes, but with conditions. Under the reliance rule introduced by GN-15 R13 (effective 10 March 2026), Class B/C/D devices already registered by Malaysia’s Medical Device Authority (MDA) after a full conformity assessment performed by its recognised assessors, and whose intended use matches the use proposed for Singapore, may qualify for the Singapore Abridged route. This turns a Malaysian registration from a single-market asset into an asset that can be reused for Singapore.

• The qualifying words are a full conformity assessment: HSA relies on an MDA registration that has been substantively reviewed, not on any listing form.
• The intended use on the Malaysian labeling must be identical to the use proposed for Singapore, so labeling alignment is a precondition, not an afterthought.
• For Class D the arithmetic is stark: with an MDA registration the Abridged route costs SGD 6,250 over 220 working days, without it the Full route costs SGD 12,000 over 310 working days.
• This is one-way reliance, not mutual recognition: a Singapore registration cannot substitute for a Malaysian registration.
• GN-15 R14 Annex 4 Part 1 now requires proactive disclosure of labeling differences, signalling that HSA grants reliance but expects labels to align.

2. Legal basis

The reliance rule originates in revision R13 of GN-15, effective 10 March 2026, while the current version is R15 of October 2026, which governs. Malaysian registrations run under the Medical Device Act 737 and the Medical Device Regulations (MDR 2012), with conformity assessments performed by conformity assessment bodies. The table below consolidates the rule and the applicable fees.

Note: the specific clause wording of R13 is subject to the official HSA GN-15 text; the current governing version is R15 (October 2026). Where any conflict appears between this consolidated summary and the official text, the official text prevails and the eligibility analysis should be repeated against it before submission.

3. Expert insights

Insight one: the full conformity assessment is the key qualifying phrase of this pathway.

Malaysian device registration operates under the Medical Device Act 737 and the Medical Device Regulations (MDR 2012), with conformity assessments executed by conformity assessment bodies (CAB). What HSA relies on is an MDA registration that has undergone substantive review, not any form of listing. When reckoning eligibility, companies must be able to produce evidence of the full conformity assessment, not merely a registration certificate. In practice this means requesting from the Malaysian authorised representative or the CAB the assessment records that sit behind the certificate, so that the Singapore submission can demonstrate the depth of review rather than assert it.

Insight two: this rule changes the economics of sequencing Southeast Asia.

Before, Malaysia and Singapore were essentially two independent investments. After R13, the Malaysian compliance investment can partly convert into faster and cheaper entry into Singapore. Taking Class D as an example:

• With an MDA registration, Abridged: SGD 6,250 / 220 working days
• Without an MDA registration, Full: SGD 12,000 / 310 working days

The difference is SGD 5,750 and 90 working days. For companies already present in Malaysia this is a free gain; for those not yet there, it is a consideration to build into the planning sequence. The saving does not come from any fee discount on the Singapore side but from the fact that the reliance route replaces the Full evaluation altogether, so the same dossier investment is reused across two markets instead of being duplicated.

Insight three: this is not mutual recognition; it is one-way reliance.

It must be stated clearly: HSA relying on MDA’s evaluation results does not mean Malaysia relies on HSA in return. One-way reliance is not mutual recognition. A Singapore registration cannot replace a Malaysian registration. Getting this relationship backwards creates substantive misrepresentation in client communication. Each market retains its own regulator, its own licence holder requirements and its own post-market obligations, and a registration in one territory confers no rights whatsoever in the other.

Insight four: scrutiny of labeling consistency will only tighten.

Annex 4 Part 1, newly added by GN-15 R14 (14 September 2026), requires applicants on the Abridged, Expedited and Immediate routes to proactively disclose the differences between the Singapore labeling and the Reference Agency approved labeling. Read together with the R13 reliance rule, HSA’s intent is clear: reliance is granted, but the labels must align. A difference that is discovered by HSA rather than disclosed by the applicant puts the entire reliance basis at risk, so the comparison of Malaysian and Singaporean labeling should happen at dossier-preparation stage, not at query stage.

4. Practical recommendations

• Check whether the existing Malaysian registration involved a full conformity assessment: not every MDA listing qualifies.
• Compare the Malaysian intended use against the use proposed for Singapore: align any inconsistency first.
• Front-load Malaysia in Southeast Asia planning: if Singapore is the target market, registering in Malaysia first may be cheaper overall.
• Prepare the labeling difference statement: Annex 4 Part 1 is mandatory.
• Do not apply the rule in reverse: a Singapore registration cannot replace a Malaysian registration, and both markets still require their own licences.

5. Verification checklist

• □ The Malaysian MDA registration has been obtained
• □ It has been confirmed that the registration followed a full conformity assessment by MDA-recognised assessors
• □ The intended uses in Malaysia and Singapore have been compared
• □ The Abridged route has been confirmed applicable and the fee calculated
• □ The labeling difference statement has been prepared (Annex 4 Part 1)
• □ The Malaysian local licence-holding arrangement has been planned in parallel (no mutual recognition)

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com